Hypertension crisis

Blood Pressure

Volumn 19, Issue 6, 2010, Pages 328-336

  Papadopoulos, Dimitris P ^a   Mourouzis, Iordanis ^a   Thomopoulos, Costas ^b   Makris, Thomas ^b   Papademetriou, Vasilios ^c  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b Helena Venizelou Maternity Hospital   (Greece)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Crisis; Emergencies; Hypertension; Urgencies

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; BUMETANIDE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESMOLOL; FENOLDOPAM; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; LOOP DIURETIC AGENT; MAGNESIUM SULFATE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ANTIHYPERTENSIVE THERAPY; AORTA DISSECTION; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CALCIUM BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSPNEA; ECLAMPSIA; ELECTROCARDIOGRAM; EPISTAXIS; FAINTNESS; HEADACHE; HUMAN; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; HYPOTENSION; INTENSIVE CARE UNIT; INTOXICATION; LUNG EDEMA; MAGNESIUM BLOOD LEVEL; MORBIDITY; MORTALITY; MUSCULOSKELETAL CHEST PAIN; NEUROLOGIC DISEASE; OTOTOXICITY; POTASSIUM BLOOD LEVEL; PREECLAMPSIA; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CRITICAL ILLNESS; HUMANS; HYPERTENSION;

EID: 78649297304     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.488052     Document Type: Review

References (74)

1. Papadopoulos DP, Papademetriou V. Resistant hypertension: Diagnosis and management. J Cardiovasc Pharmacol Ther. 2006;11:113-118.
2. Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs. 2008;68:283-297.
3. Zampaglione B, Pascale P, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies: Prevalence and clinical presentation. Hypertension. 1996;27:144-147.
4. Smith CB, Flower LW, Reinhardt CE. Control of hypertensive emergencies. Postgrad Med. 1991;89:111-116.
5. Vidt DG. Current concepts in treatment of hypertensive emergencies. Am Heart J. 1986;111:220-225.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. JAMA. 2003;289:2560-2572.
7. Vidt DG. Hypertensive crises: Emergencies and urgencies. J Clin Hypertens. 2004;6:520-525.
8. Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med. 1985;3:10-15.
9. Wallach R, Karp RB, Reves JG, Oparil S, Smith LR, James TN. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: A study of hemodynamic and humoral factors. Am J Cardiol. 1980;46:559-565.
10. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription vascular smooth muscle cells through pleiotropic activation of nuclear factor kappa-B transcription factors. Circ Res. 1999;84:695-703.
11. Mansoor M, Frishman W. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis. 2002;4:358-371.
12. Schulenburg M. Management of hypertensive emergencies: Implications for the critical care nurse. Crit Care Nurs Q. 2007;30:86-93.
13. Kaplan NM, ed. Clinical hypertension. 8th ed. Philadelphia, PA: Lippincott Williams& Wilkins; 2002. p. 339-356.
14. Di Pette DJ, Ferraro JC, Evans RR, Martin M. Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin Pharmacol Ther. 1985;38:199-204.
15. Hirschl MM, Binder M, Bur A, Herkner H, Woisetschläger C, Bieglmayer C, et al. Impact of the renin - angiotensin - aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises. J Hum Hypertens. 1997;11:177-183.
16. Friederich JA, Butterworth JF. Sodium nitroprusside: Twenty years and counting. Anesth Analg. 1995;81:152-162.
17. Robin ED, McCauley R. Nitroprusside-related cyanide poisoning: Time (long past due) for urgent, effective interventions. Chest. 1992;102:1842-184.
18. Griswold WR, Reznik V, Mendoza SA. Nitroprussideinduced intracranial hypertension [letter]. JAMA. 1981;246:2679-2680.
19. Mann T, Cohn PF, Holman LB, Green LH, Markis JE, Phillips DA, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease: Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57:732-738.
20. Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: Results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129-1135.
21. Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulphate prophylaxis. Am J Crit Care. 1992;2:19-27.
22. Murphy C. Hypertensive emergencies. Emerg Med Clin North Am. 1005;13:973-1007.
23. Goldberg ME, Clark S, Joseph J, Moritz H, Maguire D, Seltzer JL, et al. Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J. 1990;119:446-450.
24. Lund-Johansen P. Pharmacology of combined α - β-blockade: II. Haemodynamic effects of labetalol. Drugs. 1984;28 Suppl 2:35-50.
25. Kanot J, Allonen H, Kleimola T, Mäntylä R. Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1981;19:41-44.
26. Marx PG, Reid DS. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol. 1979;8:233S-238S.
27. Olsen KS, Svendsen LB, Larsen FS, Paulson OB. Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth. 1995;75:51-55.
28. Rosei EA, Trust PM, Brown JJ. Intravenous labetalol in severe hypertension. Lancet. 1975;2:1093-1094.
29. Gray RJ. Managing critically ill patients with esmolol: An ultra short-acting β-adrenergic blocker. Chest. 1988;93:398-403.
30. Lowenthal DT, Porter RS, Saris SD, Bies CM, Slegowski MB, Staudacher A. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol. 1985;56:14F-18F.
31. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925-9.
32. Smerling A, Gersony WM. Esmolol for severe hypertension following repair of aortic coarctation. Crit Care Med. 1990;18:1288-1290.
33. Gray RJ, Bateman TM, Czer LS, Conklin C, Matloff JM. Use of esmolol in hypertension after cardiac surgery. Am J Cardiol. 1985;56:49F-56F.
34. Tumlin JA, Dunbar LM, Oparil S, Buckalew V, Ram CV, Mathur V, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: A multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med. 2000;7:653-662.
35. Elliott WJ, Weber RR, Nelson KS, Oliner CM, Fumo MT, Gretler DD, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970-977.
36. Reisin E, Huth MM, Nguyen BP, Weed SG, Gonzalez FM. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 1990;15: I59-I62.
37. Prisant LM, Carr AA, Hawkins DW. Treating hypertensive emergencies. Controlled reduction of blood pressure and protection of target organs. Postgrad Med. 1990;93:92-96.
38. Ziegler MG. Advances in the acute therapy of hypertension. Crit Care Med 1992;20:1630-1631.
39. O'Connor B, Luntley JB. Acute dissection of the thoracic aorta. Esmolol is safer than and as effective as labetalol [letter;comment]. BMJ. 1995;310:875.
40. Hoshino T, Ohmae M, Sakai A. Spontaneous resolution of a dissection of the descending aorta after medical treatment with a beta blocker and a calcium antagonist. Br Heart J. 1987;58:82-84.
41. Iguchi A, Tabayashi K. Outcome of medically treated Stanford type B aortic dissection. Jpn Circ J. 1998;62:102-105.
42. Borst HG, Laas J. Surgical treatment of thoracic aortic aneurysms. Adv Cardiac Surg 1993;4:47-87.
43. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990;112:897-903.
44. Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med. 1995;333:1267-1272.
45. Dusenberry SJ, Hicks MJ, Mariani PJ. Labetalol treatment of cocaine toxicity [letter]. Ann Emerg Med. 1987;16:235.
46. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med. 1993;94:608-610.
47. Negus BH, Willard JE, Hillis LD, Lamann DB, Landau C, Snyder RW, et al. Alleviation off cocaine-induced coronary vasoconstriction with intravenous verapamil. Am J Cardiol. 1994;73:510-513.
48. Hollander JE, Carter WA, Hoffman RS. Use of phentolamine for cocaine-induced myocardial ischemia [Letter]. N Engl J Med. 1992;327:361.
49. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: A paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105:246-254.
50. Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003;348:304-311.
51. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.; The task force for the management of arterial hypertension of the European Society of Hypertension. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
52. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183: S1-S22.
53. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. Obstet Gynecol. 2002;99:159-167.
54. Magee LA, Cham C, Waterman EJ, Ohlsson A, von DP. Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis. BMJ. 2003;327:955-960.
55. Pickles CJ, Broughton PF, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol. 1992;99:964-968.
56. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: A randomized comparative trial. Obstet Gynecol. 1994;84:354-359.
57. Carbonne B, Jannet D, Touboul C, Khelifati Y, Milliez J. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol. 1993;81:908-914.
58. Papadopoulos DP, Papademetriou V. Aggressive blood pressure control and stroke prevention: Role of calcium channel blockers. J Hypertens. 2008;26:844-852.
59. Papadopoulos DP, Votteas V. Role of perindopril in the prevention of stroke. Recent Pat Cardiovasc Drug Discov. 2006;1:283-289.
60. Lavin P. Management of hypertension in patients with acute stroke. Arch Intern Med. 1986;146:66-68.
61. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-711.
62. O'Connell JE, Gray CS. Treatment of post-stroke hypertension. A practical guide. Drugs Aging. 1996;8:408-415.
63. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
64. Qureshi AI, Bliwise DL, Bliwise NG, Akbar MS, Uzen G, Frankel MR. Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: A retrospective analysis with a random effects regression model. Crit Care Med. 1999;27:480-485.
65. Varon J, Marik P. Perioperative hypertension management. Vasc Health Risk Manag. 2008;4:615-27.
66. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology. 1979;50:285-289.
67. Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297:845-50.
68. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
69. Levy JH. The ideal agent for perioperative hypertension and potential cytoprotective effects. Acta Anaesthesiol Scand Suppl. 1993;99:20-5.
70. Haas CE, LeBlanc, M. Acute postoperative hypertension: A review of therapeutic options. Am J Health System Pharm 2004;61:1661-1673.
71. Kwak YL, Oh YJ, Bang SO, Lee JH, Jeong SM, Hong YW. Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary artery bypass graft surgery. J Int Med Res. 2004;32:342-350.
72. Halpern NA, Goldberg M, Neely C, Sladen RN, Goldberg JS, Floyd J, et al. Postoperative hypertension: A multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med. 1992;20, 1637-1643.
73. Wiest D. Esmolol: A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28:190-202.
74. Hirschl MM, Binder M, Bur A, Herkner H, Woisetschläger C, Bieglmayer C, et al. Impact of the renin - angiotensin - aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises. J Hum Hypertens. 1997;11:177-183.